Spatial Acid-Associated Niches Inform Irinotecan-Based DEB-TACE in Colorectal Liver Metastases: A Multicentre Randomized Trial.

In 30 seconds

This multicentre randomised trial combined transcriptomic and spatial analyses of colorectal liver metastases (CRLM), laboratory testing of irinotecan-eluting microspheres, and clinical evaluation in 35 patients with unresectable CRLM. Acid-associated tumour features formed a spatial niche and were linked to lower predicted SN-38 IC50 in most sections. UniPearls released more irinotecan than HepaSphere at every tested pH. In the per-protocol analysis, disease control after the final DEB-TACE was 100% with UniPearls versus 68.75% with HepaSphere (p = 0.018); objective response and adverse-event frequencies were similar.

Key findings

• AcidScore and malignant epithelium increased with distance from vasculature within a niche containing SPP1 + macrophages and cancer-associated fibroblasts.
• Higher AcidScore was associated with lower predicted SN-38 IC 50 in most sections.
• UniPearls released more irinotecan than HepaSphere within 24 h at every pH tested, with the largest difference at pH 5.7.
• Per-protocol disease control after final DEB-TACE was 100% vs. 68.75% (p = 0.018); superiority was sensitive to missing-outcome assumptions.

Why it matters

The study connects spatial tumour biology with predicted drug sensitivity and local irinotecan release, offering a potential framework for understanding variation in response to liver-directed treatment. Its clinical comparison provides preliminary evidence that microsphere platform may affect disease control, while similar objective response and adverse-event frequencies and sensitivity of superiority to missing-outcome assumptions underscore the need for cautious interpretation.

What to keep in mind

The clinical trial included 35 patients, and the superiority finding was sensitive to missing-outcome assumptions. Biomarker-stratified clinical benefit remains to be established.